TickerFacts.

Atossa Therapeutics, Inc. (ATOS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2014-12-31, 2020-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest EBITDA is for the year ended 2022-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

-$27.68M
Year ended 2022-12-31
2011-12-31: -$3.41M2012-12-31: -$4.94M2013-12-31: -$10.31M2014-12-31: -$11.69M2015-12-31: -$12.49M2016-12-31: -$7.67M2017-12-31: -$7.52M2018-12-31: -$11.39M2019-12-31: -$17.21M2020-12-31: -$14.56M2021-12-31: -$20.50M2022-12-31: -$27.68M-$27.68M
2011-12-31 EBITDA (USD) 2022-12-31
Period endedEBITDAChange YoYSource filing
2022-12-31-$27.68Mn/m2024-04-01, From 2022-01-01
2021-12-31-$20.50Mn/m2023-03-22, From 2021-01-01
2020-12-31-$14.56Mn/c2022-02-28, From 2020-01-01
2019-12-31-$17.21Mn/m2021-03-31, From 2019-01-01
2018-12-31-$11.39Mn/m2020-03-26, From 2018-01-01
2017-12-31-$7.52Mn/m2019-03-28, From 2017-01-01
2016-12-31-$7.67Mn/m2018-03-08, From 2016-01-01
2015-12-31-$12.49Mn/m2017-03-21, From 2015-01-01
2014-12-31-$11.69Mn/c2016-03-30, From 2014-01-01
2013-12-31-$10.31Mn/m2015-03-30, From 2013-01-01
2012-12-31-$4.94Mn/m2014-03-27, From 2012-01-01
2011-12-31-$3.41Mn/a2013-03-28, From 2011-01-01